Robert Ha, MD
Internal Medicine · Garden Grove, CANPI 1750302188
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 800 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 800 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Nestle Healthcare Nutrition Inc.$1K
- Amgen$954
- plus $8K from 41 others
Across 1 payment — averaging $95,085 each. An ownership or investment interest held by the physician or an immediate family member.
- Overture Orthopaedics$95K
What the payments were for
- Speaking & faculty fees$5523%
- Food & beverage$15,41495%
- Education$2131%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,197 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $209,283 |
| LinzessLinaclotide | 237 | $136,111 |
| CreonLipase/Protease/Amylase | 139 | $133,737 |
| EliquisApixaban | 202 | $110,637 |
| ZenpepLipase/Protease/Amylase | 101 | $105,350 |
| VascepaIcosapent Ethyl | 292 | $105,202 |
| JanuviaSitagliptin Phosphate | 147 | $104,578 |
| FarxigaDapagliflozin Propanediol | 145 | $98,508 |
| RexultiBrexpiprazole | 61 | $93,644 |
| JardianceEmpagliflozin | 100 | $84,747 |
| ProliaDenosumab | 45 | $73,931 |
| TradjentaLinagliptin | 141 | $65,788 |
| MyrbetriqMirabegron | 115 | $62,672 |
| ZtlidoLidocaine | 70 | $44,704 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $40,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis | $1,523 | $288,707398 claims |
| Novo NordiskOzempic, Rybelsus | $2,111 | $222,579180 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Brilinta | $1,370 | $155,052226 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,204 | $150,534241 claims |
| MerckJanuvia, Janumet | $75 | $115,039171 claims |
| PfizerEliquis | $693 | $110,637202 claims |
| Aimmune Therapeutics, Inc.Zenpep | $614 | $105,350101 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $74 | $93,64461 claims |
| AmgenProlia | $954 | $73,93145 claims |
| Astellas Pharma US IncMyrbetriq | $730 | $62,672115 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $80 | $44,70470 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $65 | $29,67851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Garden Grove
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.